Considerations Following Locoregional Therapy in HCC
Considerations Following Locoregional Therapy in HCC
May 2015
- 64-year old obese female presented with fatigue and unexplained weight loss
- History of nonalcoholic fatty liver disease (NAFLD), then nonalcoholic steatohepatitis (NASH)
- Lab results: AFP= 1,500 IU/ml
- ECOG=1; Child-Pugh A
- CT revealed 1 large liver mass, right side of liver close to a major blood vessel
- No extrahepatic disease
- Liver-directed therapy with DEB-TACE was performed
- Patient reported abdominal pain following DEB-TACE and required analgesics; low-grade fever
- Patient had a complete response
- AFP= 200 IU/ml at follow up
February 2017
- Follow-up imaging showed progression and evidence of bone metastases
- Therapy was initiated with sorafenib at 400 mg BID
- Follow-up testing showed liver decompensation
Recent Videos
Related Content
Gholam Contrasts Lenvatinib With Other Options in Child-Pugh B HCC
December 21st 2024Article
During a Case-Based Roundtable® event, Pierre Gholam, MD, discussed how post hoc and real-world analyses build upon the limited available trial data for treating patients with unresectable hepatocellular carcinoma with Child-Pugh B status.
Read More
FDA Accepts NDA Resubmission of Rivoceranib and Camrelizumab in HCC
October 21st 2024Article
The new drug application resubmission of rivoceranib/camrelizumab in the first line in unresectable or metastatic hepatocellular carcinoma is supported by the final survival analysis of CARES-310 trial.
Read More
